<DOC>
	<DOC>NCT01941004</DOC>
	<brief_summary>To evaluate the safety and efficacy of fingolimod 0.5mg vs. placebo in MS patients in China</brief_summary>
	<brief_title>Safety and Efficacy of Fingolimod in MS Patients in China</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
	<mesh_term>Fingolimod Hydrochloride</mesh_term>
	<criteria>Patients must have relapsing remitting multiple sclerosis Patients with: History of chronic immune disease Certain cancers Uncontrolled diabetes Certain eye disorders Negative for varicella zoster virus IgG antibodies Certain hepatic conditions Low white blood cell count On certain immunosuppressive medications or heart medications Certain heart conditions or certain lung conditions Inability to undergo MRI scans Diagnosis of Neuromyelitis optica. Other protocol defined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>multiple sclerosis (MS)</keyword>
	<keyword>relapsing remitting multiple sclerosis (RRMS)</keyword>
	<keyword>fingolimod</keyword>
</DOC>